Visão geral da empresa
A commercial-stage pharmaceutical entity, SIGA Technologies, Inc. concentrates its operations within the United States health security market, primarily leveraging its lead product TPOXX, an antiviral medication designed for the treatment of human smallpox disease caused by the variola virus. The company functions within the Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on niche therapeutic areas and specialized formulations rather than broad consumer staples. With a market capitalization of $328.13M, an annual revenue of $94.57M, and a workforce comprising 49 employees, the organization maintains a mid-cap profile typical of specialized biopharma firms. These valuation and revenue figures indicate that SIGA operates with a relatively lean operational structure where a significant portion of its market value is derived from intellectual property and potential government contracts for smallpox countermeasures rather than mass-market pharmaceutical sales volumes.
Saúde financeira
The company reports a trailing twelve-month revenue of $94.57M alongside a net income of $23.28M and an EBITDA of $24.26M, revealing a financial structure where net income is substantially lower than EBITDA due to significant non-operating expenses or specific accounting adjustments that widen the gap between pre-tax operating performance and bottom-line profitability. Despite the reported revenue figure, the free cash flow stands at $29.07M, which suggests a robust ability to generate liquidity from operations that exceeds reported net income, providing considerable financial flexibility for reinvestment or debt reduction. The margin profile presents a complex picture with a gross margin of 47.5% indicating efficient production of TPOXX, contrasted sharply by an operating margin of -250.4% which signals substantial costs in research, development, or general administration that outweigh operating revenue, while the profit margin of 24.6% demonstrates that after all expenses including interest and taxes, the company remains profitable. On the balance sheet, the firm holds $154.97M in cash against a negligible debt load of $759,207, resulting in a debt-to-equity ratio of 0.38 that characterizes a highly conservative and low-leverage financial position. This liquidity is further underscored by a current ratio of 11.83, indicating an overwhelming capacity to meet short-term obligations with current assets. Additionally, the return on equity of 11.2% and return on assets of 6.4% reveal that management is effectively deploying capital to generate returns, particularly notable given the low debt environment and the specific operational challenges reflected in the operating margin.
Avaliação de valorização
The stock currently trades with a trailing P/E ratio of 14.31 compared to a forward P/E of 3.12, a stark disparity that implies the market anticipates a significant divergence in future earnings, potentially driven by expected changes in revenue recognition or non-recurring charges affecting the current period versus expectations for the coming year. The price-to-book ratio of 1.65 suggests that the market values the company at a premium of 65% over its net asset book value, reflecting the intangible worth of its proprietary antiviral drug portfolio and potential government contracts that are not fully captured on the balance sheet. Alternative valuation metrics further contextualize the price, with a price-to-sales ratio of 3.47 and an EV/EBITDA of 7.17, indicating that investors are willing to pay a multiple consistent with specialty drug manufacturers rather than generic competitors, despite the specific revenue growth challenges. The stock has exhibited volatility within a 52-week range bounded by a high of $9.62 and a low of $4.56, meaning the current price position fluctuates relative to this established band based on daily trading activity and sector sentiment. With a beta of 1.06, the security demonstrates price volatility that is slightly higher than the broader market benchmark, suggesting that the stock will tend to move in tandem with the S&P 500 but with amplified swings during periods of market stress or sector-specific news.
Growth & Income
The financial trajectory shows a revenue growth of -95.3% year-over-year with earnings growth listed as N/A, indicating a substantial contraction in top-line sales that complicates the comparison of earnings growth rates as they are not currently available for meaningful period-over-period analysis. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm retains all generated earnings rather than distributing them to shareholders, a strategy common for companies reinvesting capital into R&D or maintaining liquidity buffers. This approach to capital allocation prioritizes internal funding for the commercialization of TPOXX and health security initiatives over providing immediate income returns to the investor base. Consequently, the overall growth and income profile is defined by significant revenue contraction in the current fiscal period and a complete absence of dividend distributions, presenting a high-risk, high-volatility return characteristic typical of early-to-mid stage biopharmaceutical companies focused on specialized government contracts rather than steady dividend yields.